Helix BioPharma Corp. (HBP : TSX)
Common Stock
$0.90
CAD
-0.02 (-2.17%)
Last updated: 2026-11-05
Follow HBP
HBP
Helix BioPharma Corp.
WealthAwesomePerformance
1 Day
+0.00%
1 Week
-7.07%
1 Month
-6.12%
YTD
-61.67%
Key Statistics
Market Cap
$68.74M
52W High
$2.60
52W Low
$0.82
P/E Ratio
-
50 Day MA
$1.25
200 Day MA
$1.62
Beta
-0.14
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/5/2026 | $0.90 | $0.90 | $0.90 | $0.90 | $0.90 | 501 |
| 11/4/2026 | $0.92 | $0.92 | $0.92 | $0.92 | $0.92 | 0 |
| 11/3/2026 | $0.98 | $0.98 | $0.90 | $0.92 | $0.92 | 5,603 |
| 11/2/2026 | $0.95 | $1.02 | $0.90 | $1.02 | $1.02 | 14,065 |
| 10/30/2026 | $0.96 | $1.02 | $0.96 | $0.99 | $0.99 | 2,000 |
| 10/29/2026 | $0.99 | $0.99 | $0.99 | $0.99 | $0.99 | 0 |
| 10/28/2026 | $0.96 | $0.99 | $0.96 | $0.99 | $0.99 | 207 |
| 10/27/2026 | $1.04 | $1.10 | $0.98 | $1.04 | $1.04 | 5,459 |
| 10/26/2026 | $0.85 | $1.00 | $0.85 | $0.99 | $0.99 | 12,165 |
| 10/23/2026 | $0.88 | $0.88 | $0.82 | $0.82 | $0.82 | 14,135 |
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 177.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+177.8% Upside
Current Price
C$0.90
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
111.5%
Annualized
90-Day Vol
89.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.85 | C$0.58 – C$1.25 |
| 60 trading days | C$0.80 | C$0.46 – C$1.38 |
| 90 trading days | C$0.75 | C$0.39 – C$1.47 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-3.25M
- Profit Margin
- 0.00%
- ROE (TTM)
- -49.99%
- EPS (Diluted)
- -0.04
- Book Value
- 0.19
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-5
Aug 16, 2024
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About HBP
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AAB | Aberdeen International Inc. | $0.02 | +33.33% |
| XMF-A | M Split Corp | $1.99 | +17.06% |
| CNT | Century Global Commodities Corp | $0.04 | +16.67% |
| LABS | Medipharm Labs Corp | $0.07 | +16.67% |
| HSTR | Heliostar Metals Ltd. | $2.24 | +15.46% |
| DSV | Discovery Silver Corp. | $11.09 | +15.28% |
| PRL | Propel Holdings Inc | $30.53 | +15.16% |
| HMM-A | Hammond Manufacturing Company Limited | $30.00 | +15.03% |
HBP.TO news timeline
15 articles covering HBP.TO, most recent first
LatestWill Helix BioPharma Corp. (HBP) Beat Earnings Estimates in Its Next Report?
October 2026
- Why Helix BioPharma Corp. stock is rising today
- What's Going On With Helix BioPharma Corp. Stock Friday?
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock went up yesterday
- Why Helix BioPharma Corp. stock went up yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
September 2026
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock surged yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
- What's Going On With Helix BioPharma Corp. Stock Tuesday?
- Why Helix BioPharma Corp. stock fell yesterday
- What's Going On With Helix BioPharma Corp. Stock Monday?
- Why Helix BioPharma Corp. stock plummeted yesterday